Repurposing established cyclic adenosine monophosphate reducing agents for the prevention and therapy of epidermal growth factor receptor inhibitor resistance in non-small cell lung cancer

Non-small cell lung cancer (NSCLC) is a family of cancers comprised of four different histological subtypes: adenocarcinoma, squamous cell carcinoma, large cell carcinoma and carcinoids. Among the NSCLC subtypes, adenocarcinoma is the most common with incidence rising (1).